<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=10318942" created="24/05/2006" creator="Yo Shidahara"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>10318942</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Defining therapeutic targets by using <term id="T1" lex="adenovirus" sem="Virus">adenovirus</term>: blocking <term id="T2" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> inhibits both <cons id="C1" lex="(AND inflammatory_mechanism destructive_mechanism)" sem="(AND Other Other)"><frag id="F7">inflammatory</frag> and <frag id="F8">destructive</frag> <frag id="F9">mechanisms</frag></cons> in <term id="T6" lex="rheumatoid_synovium" sem="Tissue_natural">rheumatoid synovium</term> but spares <term id="T7" lex="anti-inflammatory_mediator" sem="Protein_family_or_group">anti-inflammatory mediators</term>.</sentence>
<event id="E1">
<type class="Negative_regulation"/>
<theme idref="T2"/>
<clue>Defining therapeutic targets by using adenovirus: <clueType>blocking</clueType> NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators.</clue>
</event>
<event id="E2">
<type class="Negative_regulation"/>
<theme idref="F7" idref1="F9"/>
<cause idref="E1"/>
<clue>Defining therapeutic targets by using adenovirus: blocking NF-kappaB <clueType>inhibits</clueType> both inflammatory and destructive mechanisms <clueLoc>in rheumatoid synovium</clueLoc> but spares anti-inflammatory mediators.</clue>
</event>
<event id="E3">
<type class="Negative_regulation"/>
<theme idref="F8" idref1="F9"/>
<cause idref="E1"/>
<clue>Defining therapeutic targets by using adenovirus: blocking NF-kappaB <clueType>inhibits</clueType> both inflammatory and destructive mechanisms <clueLoc>in rheumatoid synovium</clueLoc> but spares anti-inflammatory mediators.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E4">
<type class="Negative_regulation"/>
<theme idref="T7"/>
<cause idref="E1"/>
<clue>Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but <clueType><cluePolarity>spares</cluePolarity></clueType> anti-inflammatory mediators.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2">The role of the <term id="T8" lex="transcription_factor" sem="Protein_family_or_group">transcription factor</term> <term id="T9" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> in the <term id="T3" sem="Other">pathogenesis</term> of <term id="T10" lex="rheumatoid_arthritis" sem="Other">rheumatoid arthritis</term> has long been a subject of controversy.</sentence>
<event KT="Other" id="E11">
<type/>
<theme idref="T10"/>
<clue>The role of the transcription factor NF-kappaB in the <clueType>pathogenesis</clueType> <linkTheme>of</linkTheme> rheumatoid arthritis has long been a subject of controversy.</clue>
<comment>SOO</comment></event>
<event KT="Investigation" Source="Other" id="E5" uncertainty="doubtful">
<type class="Regulation"/>
<theme idref="E11"/>
<cause idref="T9"/>
<clue>The <clueType>role</clueType> <linkCause>of</linkCause> the transcription factor NF-kappaB <linkTheme>in</linkTheme> the pathogenesis of rheumatoid arthritis <clueSource>has long been</clueSource> a <clueKT>subject of controversy</clueKT>.</clue>
</event>
<sentence id="S3">We used an <term id="T11" lex="adenoviral_technique" sem="Other">adenoviral technique</term> of blocking <term id="T12" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> through <term id="T13" lex="overexpression" sem="Other">overexpression</term> of the <term id="T14" lex="inhibitory_subunit" sem="Protein_molecule">inhibitory subunit</term> <term id="T15" lex="IkappaBalpha" sem="Protein_molecule">IkappaBalpha</term>, which has the advantage that it can be used in the diseased tissue itself, with &gt;90% of the <term id="T16" lex="synovial_macrophage" sem="Cell_natural">synovial macrophages</term>, <term id="T17" lex="fibroblast" sem="Cell_natural">fibroblasts</term>, and <term id="T18" lex="T_cell" sem="Cell_natural">T cells</term> infected.</sentence>
<event Manner="High" id="E6">
<type class="Negative_regulation"/>
<theme idref="T15"/>
<clue>We used an adenoviral technique of blocking NF-kappaB through <clueType><clueManner>overexpression</clueManner></clueType> <linkTheme>of</linkTheme> the inhibitory subunit IkappaBalpha, which has the advantage that it can be used in the diseased tissue itself, with &gt;90% of the synovial macrophages, fibroblasts, and T cells infected.</clue>
</event>
<event id="E7">
<type class="Positive_regulation"/>
<theme idref="E6"/>
<clue>We used an adenoviral technique of blocking NF-kappaB through <clueType>overexpression</clueType> of the inhibitory subunit IkappaBalpha, which has the advantage that it can be used in the diseased tissue itself, with &gt;90% of the synovial macrophages, fibroblasts, and T cells infected.</clue>
</event>
<event id="E8">
<type class="Negative_regulation"/>
<theme idref="T12"/>
<cause idref="E7"/>
<clue>We used an adenoviral technique of <clueType>blocking</clueType> NF-kappaB <linkCause>through</linkCause> overexpression of the inhibitory subunit IkappaBalpha, which has the advantage that it can be used in the diseased tissue itself, with &gt;90% of the synovial macrophages, fibroblasts, and T cells infected.</clue>
</event>
<sentence id="S4">We found that the <term id="T19" lex="spontaneous_production" sem="Other">spontaneous production</term> of <term id="T20" lex="tumor_necrosis_factor_alpha" sem="Protein_molecule">tumor necrosis factor alpha</term> and other <term id="T21" lex="pro-inflammatory_cytokine" sem="Protein_family_or_group">pro-inflammatory <term id="T22" lex="cytokine" sem="Protein_family_or_group">cytokines</term></term> is <term id="T23" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term>-dependent in <term id="T24" lex="rheumatoid_synovial_tissue" sem="Tissue_natural">rheumatoid synovial tissue</term>, in contrast to the main <term id="T25" lex="anti-inflammatory_mediator" sem="Protein_family_or_group">anti-inflammatory mediators</term>, like <cons id="T26" lex="(AND IL-10 IL-11)" sem="(AND Protein_molecule Protein_molecule)"><frag id="F1"><term id="A3" sem="Protein_molecule">IL</term></frag><frag id="F2"><term id="A4" sem="Protein_molecule">-10</term></frag> and <frag id="F3"><term id="A5" sem="Protein_molecule">-11</term></frag></cons>, and the <term id="T27" lex="IL-1_receptor_antagonist" sem="Protein_molecule">IL-1 receptor antagonist</term>.</sentence>
<event id="E9">
<type class="Gene_expression"/>
<theme idref="T20"/>
<clue>We found that the spontaneous <clueType>production</clueType> <linkTheme>of</linkTheme> tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-dependent in rheumatoid synovial tissue, in contrast to the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<event id="E10">
<type class="Gene_expression"/>
<theme idref="T21"/>
<clue>We found that the spontaneous <clueType>production</clueType> <linkTheme>of</linkTheme> tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-dependent in rheumatoid synovial tissue, in contrast to the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<event id="E12">
<type class="Regulation"/>
<theme idref="E9"/>
<cause idref="T23"/>
<clue>We <clueKT>found</clueKT> that the spontaneous production of tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-<clueType>dependent</clueType> <clueLoc>in rheumatoid synovial tissue</clueLoc>, in contrast to the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<event id="E13">
<type class="Regulation"/>
<theme idref="E10"/>
<cause idref="T23"/>
<clue>We <clueKT>found</clueKT> that the spontaneous production of tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-<clueType>dependent</clueType> <clueLoc>in rheumatoid synovial tissue</clueLoc>, in contrast to the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E14">
<type class="Regulation"/>
<theme idref="T25"/>
<cause idref="T23"/>
<clue>We <clueKT>found</clueKT> that the spontaneous production of tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-<clueType>dependent</clueType> in rheumatoid synovial tissue, <linkTheme><cluePolarity>in contrast to</cluePolarity></linkTheme> the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E15">
<type class="Regulation"/>
<theme idref="A3" idref1="A4"/>
<cause idref="T23"/>
<clue>We <clueKT>found</clueKT> that the spontaneous production of tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-<clueType>dependent</clueType> in rheumatoid synovial tissue, <linkTheme><cluePolarity>in contrast to</cluePolarity></linkTheme> the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E16">
<type class="Regulation"/>
<theme idref="A3" idref1="A5"/>
<cause idref="T23"/>
<clue>We <clueKT>found</clueKT> that the spontaneous production of tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-<clueType>dependent</clueType> in rheumatoid synovial tissue, <linkTheme><cluePolarity>in contrast to</cluePolarity></linkTheme> the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E17">
<type class="Regulation"/>
<theme idref="T27"/>
<cause idref="T23"/>
<clue>We <clueKT>found</clueKT> that the spontaneous production of tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-<clueType>dependent</clueType> in rheumatoid synovial tissue, <linkTheme>i<cluePolarity>n contrast to</cluePolarity></linkTheme> the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist.</clue>
</event>
<sentence id="S5">Of even more interest, <term id="T28" lex="IkappaBalpha_overexpression" sem="Other"><term id="T29" lex="IkappaBalpha" sem="Protein_molecule">IkappaBalpha</term> overexpression</term> inhibited the production of <cons id="T30" lex="(AND matrix_metalloproteinase_1 matrix_metalloproteinase_3)" sem="(AND Protein_molecule Protein_molecule)"><frag id="F4"><term id="A6" sem="Protein_molecule">matrix metalloproteinases</term></frag> <frag id="F5"><term id="A7" sem="Protein_molecule">1</term></frag> and <frag id="F6"><term id="A8" sem="Protein_molecule">3</term></frag></cons> while not affecting their <term id="T31" lex="tissue_inhibitor" sem="Protein_molecule">tissue inhibitor</term>.</sentence>
<event Manner="High" id="E18">
<type class="Gene_expression"/>
<theme idref="T29"/>
<clue>Of even more interest, IkappaBalpha <clueType><clueManner>overexpression</clueManner></clueType> inhibited the production of matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor.</clue>
</event>
<event Manner="High" id="E19">
<type class="Positive_regulation"/>
<theme idref="E18"/>
<clue>Of even more interest, IkappaBalpha <clueType><clueManner>overexpression</clueManner></clueType> inhibited the production of matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor.</clue>
</event>
<event KT="Other" id="E20">
<type class="Gene_expression"/>
<theme idref="A6" idref1="A7"/>
<clue>Of even more interest, IkappaBalpha overexpression inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor.</clue>
</event>
<event KT="Other" id="E21">
<type class="Gene_expression"/>
<theme idref="A6" idref1="A8"/>
<clue>Of even more interest, IkappaBalpha overexpression inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor.</clue>
</event>
<event id="E22">
<type class="Negative_regulation"/>
<theme idref="E20"/>
<cause idref="E19"/>
<clue>Of even more interest, IkappaBalpha overexpression <clueType>inhibited</clueType> the production of matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor.</clue>
</event>
<event id="E23">
<type class="Negative_regulation"/>
<theme idref="E21"/>
<cause idref="E19"/>
<clue>Of even more interest, IkappaBalpha overexpression <clueType>inhibited</clueType> the production of matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E24">
<type class="Regulation"/>
<theme idref="A6" idref1="A7" idref2="T31"/>
<cause idref="E19"/>
<clue>Of even more interest, IkappaBalpha overexpression inhibited the production of matrix metalloproteinases 1 and 3 while <cluePolarity>not</cluePolarity> <clueType>affecting</clueType> <corefTheme>their tissue inhibitor</corefTheme>.</clue>
</event>
<event Polarity="Negative" assertion="non-exist" id="E25">
<type class="Regulation"/>
<theme idref="A6" idref1="A8" idref2="T31"/>
<cause idref="E19"/>
<clue>Of even more interest, IkappaBalpha overexpression inhibited the production of matrix metalloproteinases 1 and 3 while <cluePolarity>not</cluePolarity> <clueType>affecting</clueType> <corefTheme>their tissue inhibitor</corefTheme>.</clue>
</event>
<sentence id="S6">Blocking <term id="T32" lex="NF-kappaB" sem="Protein_complex">NF-kappaB</term> in the <term id="T33" lex="rheumatoid_joint" sem="Body_region">rheumatoid joint</term> thus has a very beneficial profile, reducing both the <term id="T34" lex="inflammatory_response" sem="Other">inflammatory response</term> and the <term id="T35" lex="tissue_destruction" sem="Other"><term id="T4" sem="Tissue_natural">tissue</term> destruction</term>.</sentence>
<event id="E26">
<type class="Negative_regulation"/>
<theme idref="T32"/>
<clue><clueType>Blocking</clueType> NF-kappaB <clueLoc>in the rheumatoid joint</clueLoc> thus has a very beneficial profile, reducing both the inflammatory response and the tissue destruction.</clue>
</event>
<event KT="Analysis" id="E27">
<type class="Negative_regulation"/>
<theme idref="T34"/>
<cause idref="E26"/>
<clue>Blocking NF-kappaB in the rheumatoid joint <clueKT>thus</clueKT> has a very beneficial profile, <clueType>reducing</clueType> both the inflammatory response and the tissue destruction.</clue>
</event>
<event KT="Analysis" id="E28">
<type class="Negative_regulation"/>
<theme idref="T35"/>
<cause idref="E26"/>
<clue>Blocking NF-kappaB in the rheumatoid joint <clueKT>thus</clueKT> has a very beneficial profile, <clueType>reducing</clueType> both the inflammatory response and the tissue destruction.</clue>
</event>
<sentence id="S7">The <term id="T36" lex="adenoviral_technique" sem="Other">adenoviral technique</term> described here has widespread applicability, allowing rapid testing of the effects of blocking a <term id="T37" lex="potential_therapeutic_target" sem="Other">potential therapeutic target</term> in either cultures of <term id="T38" lex="normal_cell" sem="Cell_natural">normal cells</term> or in the <term id="T39" lex="diseased_tissue" sem="Tissue_natural">diseased tissue</term> itself.</sentence>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
